Literaturverzeichnis
Priv.-Doz. Dr. med. Jan Schröder







1. Pfreundschuh M, Pohl C, Berenbeck C, Schröder J, Jung W, Schmits R, Tschiersch A, Diehl V, Gause A (1990) Detection of a soluble form of the CD30 antigen in sera of patients with lymphoma, adult T-cell leukemia and infectious mononucleosis. Int J Cancer 45: 869-874

2. Berdel WE, de Vos S, Maurer J, Oberberg D, von Marschall Z, Schröder JK, Li J, Ludwig WD, Kreuser ED, Thiel E, Herrmann F (1992) Recombinant human stem cell factor stimulates growth of a human glioblastoma cell line expressing c-kit protooncogene.
Cancer Res 52: 3498-3502

3. Harstrick A, Vanhöfer U, Schleucher N, Schröder J, Baumgart J, Scheulen ME, Wilke H, Seeber S (1995) Activity of N-benzyl-adriamycin-14-valerate (AD198), a new anthracycline derivate, in multidrug resistant human ovarian and breast carcinoma cell lines. Anticancer Drugs 6: 681-685,

4. Krismann M, Todt B, Schröder J, Gareis D, Muller KM, Seeber S, Schutte J (1995) Low specificity of cytokeratin 19 reverse transcriptase-polymerase chain reaction analyses for detection of hematogenous lung cancer dissemination. J Clin Oncol 13: 2769-2775

5. Rosskopf D, Schröder J, Siffert W (1995) Role of sodium-hydrogen exchange in the proliferation of immortalised lymphoblasts from patients with essential hypertension and normotensive subjects. Cardiovasc Res 29: 254-259

6. Vanhoefer U, Harstrick A, Wilke H, Schleucher N, Walles H, Schröder J, Seeber S (1995) Schedule-dependent antagonism of paclitaxel and cisplatin in human gastric and ovarian carcinoma cell lines in vitro. Eur J Cancer 31A: 92-97

7. Klaassen U, Harstrick A, Schleucher N, Vanhoefer U, Schröder J, Wilke H, Seeber S (1996) Activity- and schedule-dependent interactions of paclitaxel, etoposide and hydroperoxy-ifosfamide in cisplatin-sensitive and -refractory human ovarian carcinoma cell lines. Br J Cancer 74: 224-228

8. Schröder J, Esteban M, Müller MR, Kasimir-Bauer S, Bamberger U, Heckel A, Seeber S, Scheulen ME (1996) Modulation of multidrug resistance by BIBW22BS in blasts of de novo or relapsed or persistent acute myeloid leukemia ex vivo. J Cancer Res Clin Oncol; 122: 307-312

9. Schröder J, Kirch C, Flasshove M, Kalweit H, Seidelmann M, Hilger R, Seeber S, Schütte J (1996) Constitutive overexpression of the cytidine deaminase gene confers resistance to cytosine arabinoside in vitro. Leukemia 10: 1919-1924

10. Trarbach T, Scheulen, ME, Schröder J, Stuscheke M, Seeber S, Schütte J (1997) Phase II trial of first-line high-dose ifosfamide in advanced adult soft tissue sarcoma. Tumordiagn u Ther 18: 57-60

11. Kirch HC, Schröder J, Hoppe H, Esche H, Seeber S, Schütte J (1998) Recombinant gene products of two natural variants of the human cytidine deaminase gene confer different deamination rates of cytarabine in vitro. Exp Hematol 26: 421-425

12. Schröder JK, Kirch C, Seeber S, Schütte J (1998) Structural and functional analysis of the cytidine deaminase gene in patients with acute myeloid leukemia. Br J Haematol 103: 1096-1103

13. Schröder JK, Seidelmann M, Kirch HC, Seeber S, Schütte J (1998) Assessment of resistance induction to cytosine arabinoside following transfer and overexpression of the deoxycytidylate deaminase gene in vitro.Leukemia Res 22: 619-624

14. Flasshove M, Frings W, Schröder JK, Moritz T, Schütte J, Seeber S (1999) Transfer of the cytidine deaminase cDNA into hematopoetic cells. Leukemia Res 23: 1047-1053

15. Schröder JK, Kasimir-Bauer S, Seeber S, Scheulen ME (2000) In vitro effect of MDR modifiers on idarubicinol efflux in Blasts of AML. J Cancer Res Clin Oncol 126: 111-116

16 . Schröder JK, Kolkenbrock S, Tins J, Kasimir-Bauer S, Seeber S, Schütte J (2000) Analysis of thrombopoietin receptor (c-mpl) mRNA expression in de novo acute myeloid leukemia. Leukemia Res 24: 401-409

17. Werner NS, Siprashvili Z, Marquitan G, Bardenheuer W, Schröder JK, Seeber S, Huebner K, Schütte J, Opalka B (2000) Transfection and constitutive expression of the FHIT gene in renal carcinoma cell lines RCC-1 and SN12C confers differential tumor suppressive activity. Cancer Res. 2000 Jun 1;60(11):2780-5

18. Bojko P, Pawloski D, Stellberg W, Schröder JK, Seeber S. (2002) Flt3 ligand and thrombopoietin serum levels during peripheral blood stem cell mobilization with chemotherapy and recombinant human glycosylated granulocyte colony-stimulating f factor (rhu-G-CSF, lenograstim) and after high-dose chemotherapy.
Ann Hematol. 2002 Sep;81(9):522-8. Epub 2002 Sep 24.
19. Schröder J, Fietz T, Köhler A, Petersen V, Tesch H, Spring L, Fleitz A, Jänicke M, Marschner N; TMK-Group (Tumour Registry Breast Cancer). Treatment and pattern of bone metastases in 1094 patients with advanced breast cancer - Results from the prospective German Tumour Registry Breast Cancer cohort study. Eur J Cancer. 2017 Jul;79:139-148. doi: 10.1016/j.ejca.2017.03.031. Epub 2017 May 8.

20. Steinmetz T, Schröder J, Plath M, Link H, Vogt M, Frank M, Marschner N. Select item 26966Antianemic Treatment of Cancer Patients in German Routine Practice: Data from a Prospective Cohort Study-The Tumor Anemia Registry. Anemia. 2016;2016:8057650. doi: 10.1155/2016/8057650. Epub 2016 Feb 4.

21. Carl Christoph Schimanski 1, Markus Möhler, Michael Schön, Eric van Cutsem, Richard Greil, Wolf Otto Bechstein, Susanna Hegewisch-Becker, Götz von Wichert, Matthias Vöhringer, Michael Heike, Volker Heinemann, Marc Peeters, Stephan Kanzler, Stefan Kasper, Friedrich Overkamp, Jan Schröder, Daniel Seehofer, Frank Kullmann, Bernhard Linz, Irene Schmidtmann, Victoria Smith-Machnow, Ines Gockel, Hauke Lang, Peter R Galle; LICC: L-BLP25 in Patients With Colorectal Carcinoma After Curative Resection of Hepatic Metastases: A Randomized, Placebo-Controlled, Multicenter, Multinational, Double-Blinded Phase II Trial. BMC Cancer 2012 Apr 11;12:144. doi: 10.1186/1471-2407-12-144.

22. Welt A, Wiesweg M, Theurer S, Abenhardt W, Groschek M, Müller L, Schröder J, Tewes M, Chiabudini M, Potthoff K, Bankfalvi A, Marschner N, Schuler M, Breitenbücher F. Buparlisib in combination with tamoxifen in pretreated patients with hormone receptor-positive, HER2-negative advanced breast cancer molecularly stratified for PIK3CA mutations and loss of PTEN expression.
Cancer Med. 2020 Apr 30. doi: 10.1002/cam4.3092. Online ahead of print.PMID: 32352244

Übersichtsarbeiten in Zeitschriften
1. Schröder J, Schütte J (1996) Prophylaxe und Therapie zytostatikainduzierten Erbrechens. Der Onkologe 2: 593-605
Buchbeiträge – ausführlich publizierte Vorträge
1. Berenbeck C, Schroeder J, DaCosta L, Jung W, Schmits R, Diehl V, Gause A, Pfreundschuh M (1989) Detection of soluble Hodgkin-associated CD30 antigen in the sera of patients with Hodgkin´s lymphoma. In: Leukozyte typing IV. White cell differentiation antigens. Knapp W, Dörken B, Gilks WR, Rieber EP, Schmidt RE, Stein H, von dem Borne AEGKr (eds.). Oxford University Press, Oxford; p 425

2. Schröder J, Esteban M, Kasimir-Bauer S, Bamberger U, Heckel A, Scheulen ME, Seeber S (1996) In vitro modulation of multidrug resistance by BIBW22BS in blasts of de novo or relapsed or persistent AML. In: Acute Leukemias V; Hrsg: Hiddemann W, Büchner T, Wörmann B, Ritter J, Creutzig U, Plunkett W, Keating M; Springer-Verlag; pp 118-123

3. Schröder J, Schütte J (1998) Prophylaxe und Therapie zytostatikainduzierten Erbrechens. In: Therapiekonzepte Onkologie, Hrsg: Seeber S, Schütte J; Springer-Verlag; pp 1267 - 1300

4. Schröder J, Schütte J (2000) Therapie und Prophylaxe zytostatikainduzierten Erbrechens. In: Therapiekonzepte Onkologie, Hrsg: Nowrousian MR; Zuckschwerdt Verlag; pp 1 - 12
Publizierte Abstracts
1. Berenbeck C, Schröder J, DaCosta L, Junq W, Schmits R, Diehl V, Gause A, Pfrendschuh M (1989) Detection of soluble Hodgkin-related CD30-Antigen in the sera of patients with Hodgkin's lymphoma. Tissue Antigens Histocompat Immunogen 33: 308

2. Pfreundschuh M, Berenbeck C, Schröder J, DaCosta L, Jung W, Schmits R, Tschiersch A, Diehl V, Gause A (1989) Soluble CD30 antigen as a tumor marker in the sera of patients with Hodgkin's lymphoma. Proc 7th Int Congress of Immunology: 773

3. Pfreundschuh M, Berenbeck C, Schröder J, DaCosta L, Jung W, Schmits R, Tschiersch A, Diehl V, Gause A (1989). Clinical significance of soluble Hodgkin-related antigen in the sera of patients with Hodgkin's lymphoma.Proc Am Soc Clin Oncol 8: 273

4. Kreuser E-D, Schröder JK, Kintzel C, Thiel E (1991) Modulation of integrin expression by cytokines on colon cancer cell lines. Onkologie 14 (suppl 2) 92

5. Berdel WE, de Vos S, Maurer J, Oberberg D, von Marschall Z, Schröder JK, Ludwig WD, Kreuser ED, Thiel E, Herrmann F (1992) Growth modulation of glioblastoma cells by recombinant human stem cell factor (rhSCF, c-kit ligand). J Cancer Res Clin Oncol 118 (suppl): R166

6. Berdel WE, Maurer J, de Vos S, Oberberg D, von Marschall Z, Schröder JK, Ludwig WD, Kreuser ED, Herrmann F, Thiel E (1992) Recombinant human stem cell factor (rhCF, c-kit ligand) stimulates growth of a glioblastoma cell line expressing c-kit proto-oncogene. Proc Am Ass Cancer Res 33: 299

7. Kreuser E-D, Schröder JK, Kintzel C, Berdel E, Thiel E (1992) Cytokine-mediated VLA modulation can influence the adhesion of colon cancer cells to extracellular matrix proteins. Proc Am Ass Cancer Res 33: 296.

8. Schröder J, Scheulen ME, Meusers P, Reiter WW, Brandhorst D, Weimar Ch, Schoch C, Seeber S (1992) Clinical and pharmacological evalulation of the effect of dexniguldipine (B8509-035) on the treatment of patients (pts) with acute myelogenous leukemia (AML) in relapse with high-dose cytosine arabinoside (ara-C) and daunorubicin (DNR). Ann Hematol 65 (supp) A119

9. Schröder JK, Kintzel C Thiel E, Kreuser E-D (1992) Expression, modulation, and function of ß1-integrin receptors on human colon cancer cells. J Cancer Res Clin Oncol 118 (suppl): R157

10. Schröder JK, Kreuser E-D, Steinmann GG, Thiel E (1992) A new fluorometric method for measuring cell adhesion to extracellular matrix components. Proc Am Ass Cancer Res 33: 95

11. Kummer G, Schröder J, Scheulen ME (1993) Comparison of dexniguldipine, tamoxifen and verapamil as modulators of multidrug resistance in vitro. Ann Hematol 67 (supp): A72

12. Nüßler V, Scheulen ME, Kriegmair M, Lehmann M, Rathgeb F, Zech K, Wurst W, Schröder J, Seeber S, Wilmanns W (1993) Phase-I study of i.v. dexniguldipine-HCl (dex) plus vinblastine (vbl). Ann Hematol 67 (supp): A89

13. Scheulen ME, Meusers P, Schröder J, Uppenkamp M, Müller M, Reiter WW, Weimar Ch, Rathgeb F, Brittinger G, Seeber S (1993) Modulation of the efficacy of daunorubicin plus high-dose cytarabine by dexniguldipine in patients with refractory acute myeliod leukemia. Ann Hematol 67 (supp): A107

14. Scheulen ME, Meusers P, Schröder J, Uppenkamp M, Skorzec M, Weimar Ch, Brittinger G, Seeber S (1993) Effect of dexniguldipine (B935) on the efficacy of daunorubicin (DNR) plus high-dose cytosin-arabinoside (ara-C) in refractory acute myeloid leukemia (AML). Proc Am Soc Clin Oncol 12: 308

15. Schröder J, Scheulen ME, Kellner R, Seeber S (1993) In vitro modulation of multidrug resistance by dexniguldipine and verapamil in blasts of de novo or relapsed or persistant AML. Ann Hematol 67 (supp): A113

16. Scheulen ME, Müller M, Wermes R, Schröder J, Schütte J, Skorzek M, Meusers P, Brittinger G, Seeber S (1994) Cellular pharmacokinetics of idarubicin and idarubicinol in patients with acute myeloid leukemia: Correlation with clinical response and P-glycoprotein expression. Onkologie 17 (suppl 2): 127

17. Scheulen ME, Wermes R, Müller M, Schröder J, Schütte J, Skorzek M, Käding J, Meusers P, Brittinger G, Seeber S (1994) Cellular pharmacokinetics of idarubicin and idarubicinol in patients with acute myeloid leukemia: Correlation with clinical response and P-glycoprotein expression. Ann Hematol 68 (supp I) A5

18. Scheulen ME, Müller M, Schröder J, Wermes R, Schütte J, Skorek M, Käding J, Meusers P, Brittinger G, Seeber S (1994) Correlation of cellular pharmacokinetics of idarubicin and idarubicinol, P-glycoprotein expression and response in patients with acute myeloid leukemia. Proc Am Ass Cancer Res 35: 428

19. Scheulen ME, Nüßler V, Kriegmair M, Lehmann M, Rathgeb F, Zech K, Wurst W, Kloth B, Schröder J, Willmanns W, Seeber S (1994) Phase-I study of i.v. dexniguldipine plus vinblastine. Proc Am Soc Clin Oncol 13: 156

20. Schröder J, Scheulen ME, Esteban M, Heckel A, Bamberger U, Seeber S (1994) In vitro modulation of multidrug resistance by BIBW22BS in blasts of AML. Proc Am Ass Cancer Res 35: 358

21. Schröder J, Scheulen ME, Esteban M, Heckel A, Bamberger U, Seeber S (1994) In vitro modulation of multidrug resistance by BIBW22BS in blasts of de novo or relapsed or persistent AML. Ann Hematol 68 (supp I) A26

22. Schröder J, Esteban M, Skubatz M, Scheulen ME, Meusers P, Brittinger G, Seeber S (1994) Effects of mdr-modulators on the efflux of idarubicinol from blasts of acute myeloid leukemia ex vivo. Onkologie 17 (suppl 2): 135

23. Scheulen ME, Meusers P, Schröder J, Uppenkamp M, Skorzek M, Weimar Ch, Brittinger G, Seeber S (1995) Effect of Dexniguldipine (B935) on the efficacy of daunorubicin (DNR) plus high-dose cytosine-arabinoside (ara-C) in refractory acute myeloid leukemia (AML). Proc Am Ass Cancer Res 36: 203

24. Schröder J, Scheulen ME, Esteban M, Trarbach T, Schneider A, Seeber S (1995) In vitro modulation of multidrug resistance by nordexverapamil in blasts of AML. Onkologie 18 (suppl 2): 140

25. Schröder J, Kirch C, Flasshove M, Kalweit H, Todt B, Chisky A, Seeber S, Schütte J (1996) Constitutive overexpression of the cytidine deaminase gene confers resistance to cytosine arabinoside in vitro. Ann Hematol 73 (suppl II): A4

26. Flasshove M, Moritz T, Schröder J, Seeber S, Schütte J (1996) Transfer of cytidine deaminase (CDD) into hematopoietic cells increase resistance to cytarabine (ARA-C). Blood (suppl), 298b

27. Klaassen U, Harstrick A, Schleucher N, Vanhoefer U, Schröder J, Wilke H, Seeber S (1996) Activity of schedule dependent interactions of paclitaxel, etoposid and ifosfamide in cisplatin-sensitive and cisplatin-refractory human ovarian carcinoma cell lines. Proc Am Ass Cancer Res 37: 376

28. Nowrousian MR, Rauh J, Zielske D, Mengelkoch B, Kasper Ch, Fossa A, Eberhardt W, Schröder J, Stuschke M, Metz KA, Sack H, Seeber S (1996) Response-adapted combination chemotherapy (CEBOPP/VIML) followed by radiotherapy for bulky or advanced-stage Hodgkin´s disease. Ann Hematol 73 (suppl II): A150

29. Schröder J, Kirch C, Chisky A, Todt B, Kalweit H, Seeber S, Schütte J (1996) Structural analysis of the cytidine deaminase gene in patients with acute myeloid leukemia. Ann Hematol 73 (suppl II): A30

30. Trarbach T, Scheulen ME, Schröder J, Eggert J, Seeber S, Schütte J (1996) Phase I-II trial of sequential high-dose ifosfamide and anthracyclines ± cyclosporine A in advanced adult soft tissue sarcoma. Ann Hematol 73 (suppl II): A81

31. Flasshove M, Moritz T, Schröder J, Seeber S, Schütte J (1997) Retroviral gene transfer of cytidine deaminase cDNA into hematopoietic cells. J Mol Med 75, B216

32. Flasshove M, Moritz T, Schröder J, Czeranski M, Seeber S, Schütte J (1997) Cytidine deaminase (CDD) cDNA transfer confers resistance to cytosine arabinoside (ARA-C) Onkologie 20 (suppl): 179

33. Kirch HC, Schröder J, Hoppe H, Esche H, Seeber S, Schütte J (1997) Recombinant gene products of two natural variants of the human cytidine deaminase (CDD) gene confer different deamination rates of cytosine arabinoside in vitro. J Mol Med 75: B215

34. Schröder JK, Seidelmann M, Kirch CH, Hoppe H, Seeber S, Schütte J (1997) Analysis of the cytidine deaminase (CDD) gene and CDD enzyme activities in patients with de novo and refractory acute myeloid leukemia. J Mol Med 75: B215

35. Schröder J, Seidelmann M, Kirch C, Kallweit H, Seeber S, Schütte J (1997) Structural analysis of the cytidine deaminase gene in patients with acute myeloid leukemia. Proc Am Soc Clin Oncol 16: 5a

36. Flasshove M. Frings W, Moritz T, Schröder J, Seeber S, Schütte J (1998) Retroviral gene transfer of cytidine deaminase (CDD) into primary hematopoetic cells. Blood 92 (suppl 1): 377b

37. Nowrousian MR, Welt A, Fossa A, Kasper Ch, Schröder J, Kuhlmann S, Schütte J, Kloke O, Stuschke M, Schüle-Hein K, Metz KA, Leder LD, Sack H, Seeber S (1998) Response-adapted sequential combination chemotherapy (CEBOPP/VIML) followed by radiotherapy for bulky or advanced-stage Hodgkin´s disease. Ann Oncol 9 (suppl 4): 107

38. Schröder J, Kolkenbrock S, Tins J, Kasimir-Bauer S, Beelen DW, Seeber S, Schütte J (1998) Analysis of thrombopoietin receptor (c-mpl) mRNA expression in de novo acute myeloid leukemia. Ann Hematol 77 (suppl II): 203

39. Bojko P, Daneshvaran J, Hapke G, Trarbach T, Schröder J, Harstrick A, Seeber S (1999) Comparison of early vs. late antibiotic prophylaxis in patients (pts) receiving high dose chemotherapy (HDC) with peripheral blood stem cell (pbsc) transplantation. Blood 94 (suppl 1): 365 b

40. Borquez D, Matulla-Markus A, Klaassen U, Beling C, Mayer S, Kloke O, Nowrousian MR, Schröder J, Seeber S, Harstrick A (1999) Evaluation of a complex treatment program including local therapy and high-dose chemotherapy with PBSC support in metatatic breast cancer. Onkologie 22 (suppl 1): 30

41. Harstrick A, Schleucher N, Andresen E, Schütte J, Schröder J, Hapke G, Bojko P, Wilke H, Seeber S (1999) Sequential high dose chemotherapy in metastatic recurrent germ cell cancer. Onkologie 22 (suppl 1): 215

42. Harstrick A, Schleucher N, Andresen E, Kolkenbrock S, Schröder J, Welt A, Schütte J, Kloke O, Nowrousian MR, Bojko P, Klaassen U, Seeber S (1999)
Tandem high-dose chemotherapie with carboplatin, etoposid and cyclophosphamide followed by peripheral blood stem cell retransfusion in cisplatin refractory germ cell cancer patients. Proc Am Soc Clin Onco 18: 327a

43. Schroeder J, Tasci E, Nolte-Ernsting C, Michels P, Wetzel N, Scheiner-Sparna R, Stang A (2020)
Adjunctive local therapy in metastatic colorectal cancer in an unselected cohort: Improved patient-survival in comparison to systemic therapies. J Clin Oncol 38: 2020 (suppl; abstr 4096)





Kontakt

● Tel: 0208-76981
● FAX: 0208-76982
● Email: anmeldung@onkologie-mh.de
Adresse

Schulstraße 13
45468 Mülheim